|
US1548716A
(en)
|
1924-10-02 |
1925-08-04 |
Fournier Santiago Emilien |
Process for the manufacture of artificial freestone
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
WO1993003769A1
(en)
|
1991-08-20 |
1993-03-04 |
THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES |
Adenovirus mediated transfer of genes to the gastrointestinal tract
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
JPH08503855A
(ja)
|
1992-12-03 |
1996-04-30 |
ジェンザイム・コーポレイション |
嚢胞性線維症に対する遺伝子治療
|
|
ATE304604T1
(de)
|
1993-06-24 |
2005-09-15 |
Frank L Graham |
Adenovirus vektoren für gentherapie
|
|
DE69434594T2
(de)
|
1993-10-25 |
2006-09-21 |
Canji, Inc., San Diego |
Rekombinante adenoviren-vektor und verfahren zur verwendung
|
|
US5696234A
(en)
*
|
1994-08-01 |
1997-12-09 |
Schering Corporation |
Muteins of mammalian cytokine interleukin-13
|
|
US6682741B1
(en)
|
1998-06-10 |
2004-01-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
β2 microglobulin fusion proteins and high affinity variants
|
|
US7078387B1
(en)
|
1998-12-28 |
2006-07-18 |
Arch Development Corp. |
Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
|
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
|
AU2000277350A1
(en)
|
2000-09-29 |
2002-04-15 |
Steven J. Bark |
Labeled peptides, and processes and intermediates useful for their preparation
|
|
US20040146520A1
(en)
*
|
2001-03-19 |
2004-07-29 |
Gavin Screaton |
Materials and methods relating to immune suppression
|
|
IL158418A0
(en)
|
2001-04-19 |
2004-05-12 |
Scripps Research Inst |
In vivo incorporation of unnatural amino acids
|
|
US8895020B2
(en)
|
2002-04-19 |
2014-11-25 |
Washington University |
Single chain trimers and uses therefor
|
|
WO2005081716A2
(en)
|
2003-11-24 |
2005-09-09 |
The Johns Hopkins University |
DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
|
|
GB0329146D0
(en)
|
2003-12-16 |
2004-01-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
UA92913C2
(ru)
|
2005-06-20 |
2010-12-27 |
Кадила Хелткере Лимитед |
Экспрессионный вектор и способы продуцирования высоких уровней белков
|
|
US7521195B1
(en)
|
2005-07-21 |
2009-04-21 |
Celera Corporation |
Lung disease targets and uses thereof
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
DK2402754T4
(da)
|
2006-03-06 |
2023-08-28 |
Amunix Operating Inc |
Ustrukturerede rekombinante polymerer og anvendelser deraf
|
|
US8992937B2
(en)
|
2006-08-28 |
2015-03-31 |
Washington University |
Disulfide trap MHC class I molecules and uses therefor
|
|
MX2010001684A
(es)
|
2007-08-15 |
2010-04-21 |
Amunix Inc |
Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
|
|
JP2012500652A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
標的化共刺激ポリペプチドおよび癌を処置するための使用方法
|
|
US20110318380A1
(en)
|
2008-10-01 |
2011-12-29 |
Dako Denmark A/S |
MHC Multimers in Cancer Vaccines and Immune Monitoring
|
|
EP2365979A2
(en)
*
|
2008-10-22 |
2011-09-21 |
Biogen Idec MA Inc. |
Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins
|
|
MX346450B
(es)
|
2008-11-30 |
2017-03-17 |
Immusant Inc * |
Composiciones y métodos para el tratamiento de la enfermedad celíaca.
|
|
CN108530543B
(zh)
|
2009-02-03 |
2023-06-23 |
阿穆尼克斯制药公司 |
延伸重组多肽和包含该延伸重组多肽的组合物
|
|
US9238878B2
(en)
|
2009-02-17 |
2016-01-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
|
WO2012037551A2
(en)
|
2010-09-17 |
2012-03-22 |
Irx Therapeutics, Inc. |
Primary cell-derived biologic and wt1 synthetic long peptide vaccine
|
|
US20120141537A1
(en)
|
2010-11-18 |
2012-06-07 |
Pease Larry R |
Enhancing t cell activation using altered mhc-peptide ligands
|
|
WO2012088446A1
(en)
*
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
JP6162606B2
(ja)
|
2011-01-14 |
2017-07-12 |
レッドウッド バイオサイエンス， インコーポレイテッド |
アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法
|
|
ES2676878T3
(es)
|
2011-03-03 |
2018-07-25 |
Zymeworks Inc. |
Diseño de armazón de heteromultímero multivalente y constructos
|
|
JP2014513948A
(ja)
|
2011-04-20 |
2014-06-19 |
ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション |
β２ミクログロブリン欠損細胞
|
|
US9701749B2
(en)
|
2011-08-11 |
2017-07-11 |
Ono Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising PD-1 agonist
|
|
WO2013030620A2
(de)
|
2011-08-30 |
2013-03-07 |
Jacobs University Bremen Ggmbh |
Gen codiert für ein mhc-klasse-i-molekül, plasmid, expressionssystem protein, multimer, reagenz und kit zum analysieren einer t-zellen-frequenz
|
|
CA2861206C
(en)
|
2012-01-13 |
2021-07-06 |
Richard J. O'reilly |
Immunogenic wt-1 peptides and methods of use thereof
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
JP6498600B2
(ja)
|
2012-06-08 |
2019-04-10 |
ストロ バイオファーマ インコーポレーテッド |
部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
|
|
EP2863955B1
(en)
|
2012-06-26 |
2016-11-23 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
|
JP6578206B2
(ja)
*
|
2012-07-19 |
2019-09-18 |
レッドウッド バイオサイエンス， インコーポレイテッド |
Ｃｄ２２に特異的な抗体およびその使用方法
|
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
|
US10048271B2
(en)
|
2012-12-11 |
2018-08-14 |
Albert Einstein College Of Medicine, Inc. |
Methods for high throughput receptor:ligand identification
|
|
SG11201605632SA
(en)
|
2014-01-21 |
2016-08-30 |
Einstein Coll Med |
Cellular platform for rapid and comprehensive t-cell immunomonitoring
|
|
CN106456798B
(zh)
|
2014-04-25 |
2021-02-12 |
瑞纳神经科学公司 |
具有高药物负载的抗体-药物缀合物
|
|
KR102486180B1
(ko)
|
2014-06-06 |
2023-01-11 |
레드우드 바이오사이언스 인코포레이티드 |
항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
|
|
PT3480213T
(pt)
*
|
2014-06-18 |
2020-02-04 |
Albert Einstein College Medicine |
Polipéptidos syntac e utilizações dos mesmos
|
|
EP3286222A4
(en)
|
2015-03-23 |
2018-08-08 |
The Johns Hopkins University |
Hla-restricted epitopes encoded by somatically mutated genes
|
|
WO2016153572A1
(en)
|
2015-03-25 |
2016-09-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific multivalent fusion proteins
|
|
AU2016256911B2
(en)
|
2015-05-07 |
2022-03-31 |
Agenus Inc. |
Anti-OX40 antibodies and methods of use thereof
|
|
CN108474791B
(zh)
|
2015-10-22 |
2022-07-08 |
朱诺治疗学有限公司 |
培养细胞的方法及用于该方法的试剂盒和设备
|
|
CA3014458A1
(en)
*
|
2016-03-02 |
2017-09-08 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
AU2017225787B2
(en)
*
|
2016-03-03 |
2021-09-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
CR20180519A
(es)
|
2016-03-31 |
2019-03-05 |
Neon Therapeutics Inc |
Neoantígenos y métodos de su uso
|
|
CN115073581A
(zh)
*
|
2016-05-04 |
2022-09-20 |
美国安进公司 |
用于扩增t调节性细胞的白细胞介素-2突变蛋白
|
|
US11505591B2
(en)
|
2016-05-18 |
2022-11-22 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
AU2017266905B2
(en)
|
2016-05-18 |
2022-12-15 |
Albert Einstein College Of Medicine, Inc. |
Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
|
|
DE102016222109A1
(de)
|
2016-11-10 |
2018-05-17 |
Robert Bosch Gmbh |
Brennstoffzellensystem
|
|
KR102760578B1
(ko)
|
2016-12-22 |
2025-02-03 |
큐 바이오파마, 인크. |
T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
|
|
US11851471B2
(en)
|
2017-01-09 |
2023-12-26 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
IL269000B2
(en)
|
2017-03-15 |
2024-06-01 |
Cue Biopharma Inc |
Methods for modulating an immune response
|
|
MX2019010812A
(es)
|
2017-03-17 |
2019-12-11 |
Hutchinson Fred Cancer Res |
Proteinas de fusion inmunomoduladoras y sus usos.
|
|
TW201920249A
(zh)
|
2017-09-07 |
2019-06-01 |
美商信號生物製藥公司 |
具有結合位點之t細胞調節多聚體多肽及其使用方法
|
|
TW201925235A
(zh)
|
2017-09-07 |
2019-07-01 |
美商信號生物製藥公司 |
具有化學結合位點之抗原呈現多肽及其使用方法
|
|
EP3678677A4
(en)
|
2017-09-07 |
2021-06-16 |
Cue Biopharma, Inc. |
Antigen-presenting polypeptides and methods of use thereof
|
|
EA202090471A1
(ru)
|
2017-09-07 |
2020-06-10 |
Кью Биофарма, Инк. |
Модулирующие т-клетки мультимерные полипептиды и способы их применения
|
|
CN111886241A
(zh)
|
2018-01-09 |
2020-11-03 |
库尔生物制药有限公司 |
多聚体t细胞调节多肽及其使用方法
|
|
SG11202009761YA
(en)
|
2018-04-02 |
2020-10-29 |
Pact Pharma Inc |
Peptide-mhc compacts
|
|
TWI856047B
(zh)
|
2018-12-19 |
2024-09-21 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
WO2020132136A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2020132368A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
WO2020132365A2
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
WO2020132135A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
AU2019401183A1
(en)
|
2018-12-19 |
2021-08-12 |
Cue Biopharma, Inc. |
Multimeric T-cell modulatory polypeptides and methods of use thereof
|
|
WO2020132366A2
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
CA3130750A1
(en)
|
2019-02-20 |
2020-08-27 |
Rubius Therapeutics, Inc. |
Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use
|
|
JP7691927B2
(ja)
|
2019-03-06 |
2025-06-12 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
|
|
EP3935080A4
(en)
|
2019-03-06 |
2023-04-05 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
AU2020282736B2
(en)
|
2019-05-29 |
2025-10-30 |
Cue Biopharma, Inc. |
Multimeric T-cell modulatory polypeptides and methods of use thereof
|
|
JP2022536581A
(ja)
|
2019-06-19 |
2022-08-18 |
キュー バイオファーマ， インコーポレイテッド |
多量体ｔ細胞調節性ポリペプチド及びその使用方法
|
|
WO2021055594A1
(en)
|
2019-09-20 |
2021-03-25 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides and methods of use thereof
|
|
MX2022003744A
(es)
|
2019-09-30 |
2022-07-21 |
Adimab Llc |
Variantes del dominio ch1 modificadas geneticamente para el emparejamiento preferencial a cadenas ligeras y anticuerpos multiespecíficos que comprenden las mismas.
|
|
AU2020370292A1
(en)
|
2019-10-23 |
2022-03-03 |
Cue Biopharma, Inc. |
T-cell modulatory chimeric molecules and methods of use thereof
|
|
EP4048402A4
(en)
|
2019-10-23 |
2023-11-22 |
Cue Biopharma, Inc. |
MODIFIED CYTOTOXIC T CELLS AND METHOD OF USE THEREOF
|
|
WO2021195108A1
(en)
|
2020-03-24 |
2021-09-30 |
Cue Biopharma, Inc. |
T cell modulatory polypeptides and methods of use thereof
|
|
WO2021195411A1
(en)
|
2020-03-25 |
2021-09-30 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
WO2021231376A2
(en)
|
2020-05-12 |
2021-11-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2021242935A1
(en)
|
2020-05-26 |
2021-12-02 |
Cue Biopharma, Inc. |
Antigen presenting polypeptide complexes and methods of use thereof
|
|
KR20230052881A
(ko)
|
2020-07-14 |
2023-04-20 |
큐 바이오파마, 인크. |
접합 부위를 갖는 t-세포 조절 폴리펩티드 및 이의 사용 방법
|
|
WO2022056015A1
(en)
|
2020-09-09 |
2022-03-17 |
Cue Biopharma, Inc. |
Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereof
|
|
EP4211149A4
(en)
|
2020-09-09 |
2024-10-09 |
Cue Biopharma, Inc. |
MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
|
|
WO2022099157A1
(en)
|
2020-11-06 |
2022-05-12 |
Cue Biopharma, Inc. |
Antigen presenting polypeptide complexes and methods of use thereof
|
|
WO2022099156A2
(en)
|
2020-11-06 |
2022-05-12 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides with conjugation sites and methods of use thereof
|
|
WO2022119958A1
(en)
|
2020-12-02 |
2022-06-09 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
CA3212382A1
(en)
|
2021-03-19 |
2022-09-22 |
Ronald D. Seidel Iii |
T-cell modulatory polypeptides and methods of use thereof
|
|
JP2024518680A
(ja)
|
2021-03-19 |
2024-05-02 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節ポリペプチド及びその使用方法
|
|
JP2024516610A
(ja)
|
2021-04-21 |
2024-04-16 |
キュー バイオファーマ， インコーポレイテッド |
Ｍｈｃクラスｉｉ ｔ細胞調節ポリペプチド及びその使用方法
|
|
CN117337298A
(zh)
|
2021-04-21 |
2024-01-02 |
Cue生物制药股份有限公司 |
治疗1型糖尿病(t1d)的mhc ii类t细胞调节多肽及其使用方法
|
|
WO2022226054A2
(en)
|
2021-04-21 |
2022-10-27 |
Cue Biopharma, Inc. |
Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof
|
|
WO2023081718A1
(en)
|
2021-11-04 |
2023-05-11 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|